Straus SK, Hancock REW. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta. 2006;1758:1215–23. https://doi.org/10.1016/j.bbamem.2006.02.009.

CAS  Article  PubMed  Google Scholar 

US FDA. FDA approved drug products: Cubicin (daptomycin) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208385s005lbl.pdf. Accessed 7 Aug 2022.

Jones TW, Jun AH, Michal JL, Olney WJ. High dose daptomycin and clinical applications. Ann Pharmacother. 2021;55:1363–78. https://doi.org/10.1177/1060028021991943.

CAS  Article  PubMed  Google Scholar 

Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1–10. https://doi.org/10.1093/cid/cis966.

Article  PubMed  Google Scholar 

Roux S, Valour F, Karsenty J, Gagnieu M-C, Perpoint T, Lustig S, et al. Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center. BMC Infect Dis. 2016;16:83. https://doi.org/10.1186/s12879-016-1420-7.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Telles JP, Cieslinski J, Tuon FF. Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review. Braz J Infect Dis. 2019;23:191–6. https://doi.org/10.1016/j.bjid.2019.05.006.

Article  PubMed  Google Scholar 

Lora-Tamayo J, Parra-Ruiz J, Rodríguez-Pardo D, Barberán J, Ribera A, Tornero E, et al. High doses of daptomycin (10 mg/kg/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study. Diagn Microbiol Infect Dis. 2014;80:66–71. https://doi.org/10.1016/j.diagmicrobio.2014.05.022.

CAS  Article  PubMed  Google Scholar 

Traunmüller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010;65:1252–7. https://doi.org/10.1093/jac/dkq109.

CAS  Article  PubMed  Google Scholar 

Montange D, Berthier F, Leclerc G, Serre A, Jeunet L, Berard M, et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother. 2014;58:3991–6. https://doi.org/10.1128/AAC.02344-14.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Grillon A, Argemi X, Gaudias J, Ronde-Ousteau C, Boeri C, Jenny J-Y, et al. Bone penetration of daptomycin in diabetic patients with bacterial foot infections. Int J Infect Dis. 2019;85:127–31. https://doi.org/10.1016/j.ijid.2019.05.011.

CAS  Article  PubMed  Google Scholar 

Morrisette T, Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Rybak MJ. The evolving reduction of vancomycin and daptomycin susceptibility in MRSA: salvaging the gold standards with combination therapy. Antibiotics. 2020;9:762. https://doi.org/10.3390/antibiotics9110762.

CAS  Article  PubMed Central  Google Scholar 

Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin Non-susceptibility in vancomycin-intermediate Staphylococcus Aureus (VISA) and heterogeneous-VISA (HVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011;66:1057–60. https://doi.org/10.1093/jac/dkr066.

CAS  Article  PubMed  Google Scholar 

Siala W, Mingeot-Leclercq M-P, Tulkens PM, Hallin M, Denis O, Van Bambeke F. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2014;58:6385–97. https://doi.org/10.1128/AAC.03482-14.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Stewart PS, Davison WM, Steenbergen JN. Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother. 2009;53:3505–7. https://doi.org/10.1128/AAC.01728-08.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318–23. https://doi.org/10.1128/AAC.47.4.1318-1323.2003.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245–9. https://doi.org/10.1128/AAC.00247-06.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177–80. https://doi.org/10.1086/600039.

CAS  Article  PubMed  Google Scholar 

Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, et al. Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012;56:5626–32. https://doi.org/10.1128/AAC.00038-12.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63–8. https://doi.org/10.1128/AAC.48.1.63-68.2004.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d’Ettorre G, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19:732–9. https://doi.org/10.1007/s10156-013-0559-z.

CAS  Article  PubMed  Google Scholar 

Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50:1568–74. https://doi.org/10.1086/652767.

CAS  Article  PubMed  Google Scholar 

Samura M, Takada K, Yamamoto R, Ito H, Nagumo F, Uchida M, et al. Population pharmacokinetic analysis and dosing optimization based on unbound daptomycin concentration and cystatin C in nonobese elderly patients with hypoalbuminemia and chronic kidney disease. Pharm Res. 2021;38:1041–55. https://doi.org/10.1007/s11095-021-03058-0.

CAS  Article  PubMed  Google Scholar 

Goutelle S, Roux S, Gagnieu M-C, Valour F, Lustig S, Ader F, et al. Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections. Antimicrob Agents Chemother. 2016;60:3148–51. https://doi.org/10.1128/AAC.02597-15.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bricca R, Goutelle S, Roux S, Gagnieu M-C, Becker A, Conrad A, et al. Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. J Antimicrob Chemother. 2019;74:1012–20. https://doi.org/10.1093/jac/dky541.

CAS  Article  PubMed  Google Scholar 

Garreau R, Bricca R, Gagnieu M-C, Roux S, Conrad A, Bourguignon L, et al. Lyon Bone and Joint Infection Study Group. Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. J Antimicrob Chemother. 2021;76:1250–7. https://doi.org/10.1093/jac/dkab006.

CAS  Article  PubMed  Google Scholar 

Anonymous reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. https://www.ema.europa.eu/en/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation. Accessed 12 Jan 2022.

Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992;36:318–25. https://doi.org/10.1128/AAC.36.2.318.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact. 2004;150:137–47. https://doi.org/10.1016/j.cbi.2004.08.004.

CAS  Article  PubMed  Google Scholar 

Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13:519–47. https://doi.org/10.1208/s12248-011-9290-9.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kreft B, de Wit C, Krech R, Marre R, Schulz E, Sack K. Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats. J Antimicrob Chemother. 1990;25:635–43. https://doi.org/10.1093/jac/25.4.635.

CAS  Article  PubMed  Google Scholar 

Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and Madin-Darby canine kidney cells. Antimicrob Agents Chemother. 2007;51:2748–57. https://doi.org/10.1128/AAC.00090-07.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Benefield RJ, Slechta ES, Gast CM, Spivak ES, Hanson KE, Alexander DP. Comparison of the drug-drug interaction potential of daptomycin in combination with rifampin in healthy adult volunteers. Antimicrob Agents Chemother. 2018;62:e01525-e1618. https://doi.org/10.1128/AAC.01525-18.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y-F, Sun T-L, Sun Y, Huang HW. Interaction of daptomycin with lipid bilayers: a lipid extracting effect. Biochemistry. 2014;53:5384–92. https://doi.org/10.1021/bi500779g.

CAS  Article  PubMed  Google Scholar 

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, et al. Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint. Clin Infect Dis. 2019;68:1650–7. https://doi.org/10.1093/cid/ciy749.

CAS  Article  PubMed